Skip to contentT
TuHURA Biosciences, Inc.
T
HURATuHURA Biosciences, Inc. Q1 2017 · 10-Q
Revenue—
Net Income-$2.29M-$2.29MN/M vs Q1 2016 EPS, diluted—
Operating Cash Flow-$1,613,082N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
TuHURA Biosciences, Inc. · CIK 1498382 · Engraved from SEC EDGAR
ended Sep 30, 2016 · filed Nov 10, 2016 · 41 d after period end